By Andrew Silver SHANGHAI (Reuters) -Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

In response, Novo is reorganizing its leadership team following the surprise ouster of Chief Executive Lars Fruergaard ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

Sonia Saxena’s five-year weight loss journey transformed her from an overwhelmed mother at 80 kg to a disciplined, empowered ...

A novel medication out of Sweden has shown some of the same promise in melting belly fat — without making your stomach churn.

The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to ...

A GLP-1 drug led to fewer days with headaches, a small pilot study of migraine sufferers shows. It may work by lowering pressure inside the head.

“Our findings show liraglutide may be effective for treating stubborn, high-frequency migraines in patients with obesity, and ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...